Rosiglitazone and Metformin rapid improvement of insulin resistance.doc

 PAGE \* MERGEFORMAT 7 Rosiglitazone and Metformin rapid improvement of insulin resistance Of: Qimei Ping Wei Cuiying Wu Shimin [Abstract] Objective: To overweight / or obese patients with type 2 diabetes to explore the ideal therapy. Methods: 80 patients with adequate living intervention plus metformin treatment for 2 months or more, is not the ideal blood glucose control in type 2 diabetes who were randomly plus Rosiglitazone and placebo treatment for 12 weeks after treatment were observed between the fasting plasma glucose, 2 h postprandial blood glucose, glycated hemoglobin and insulin resistance. Results: After 12 weeks of rosiglitazone treatment group than in the placebo group fasting plasma glucose, glycosylated hemoglobin, insulin resistance index were significantly reduced. Conclusions: Rosiglitazone and Metformin for rapid improvement of the overweight / obese patients with type 2 diabetes insulin resistance, is the ideal treatment of such patients. [Keywords:] overweight; obesity; 2 diabetes mellitus; insulin resistance; rosiglitazone Type 2 diabetes, insulin resistance is the major pathophysiological mechanisms. Obesity and type 2 diabetes patients with insulin resistance is more obvious, with more severe metabolic disorders and higher risk of cardiovascular events, not suitable for insulin treatment. So for overweight / or obese and type 2 diabetic patients find convenient and optimal treatment of positive significance, this article aims to explore whether rosiglitazone combined with metformin can quickly improve the overweight / obese patients with type 2 diabetes, insulin resistance. 1 Subjects and methods 1.1 Object Select from February 2008 to December 2009 for the first time in our hospital endocrine clinic diagnosed with type 2 diabetes 3 081 cases, 454 cases of which 2 males and 26 females, aged 28 to 66 years, mean age 45 years, body mass index (BMI) 25.3 ~ 32.6 kg/m2, the average BMI was 27.9 kg/m2. male Waist 87 ~ 105